Kiromic Biopharma, Inc.’s Post

Results of Tropion lung study

Did you know? A week ago The FDA has approved #Alecensa (alectinib) for adjuvant treatment in early-stage ALK-positive non-small cell lung cancer following tumor resection #FDAApproval #Lungcancer #Genentech #Alecensa #Oncology #Innovation #Lungcancer #NSCLC #RASLifescienceSolutions

Unlocking New Horizons in HER2-Negative Breast Cancer Treatment Pipeline: In-Depth Analysis of Clinical Trials, Therapies, and FDA Approvals – Deep dive into recent developments #Business #HealthMedicine #MarketingSales #PharmaceuticalsBiotech

The FDA has given the green light to #Alecensa (alectinib) for adjuvant treatment in early-stage ALK-positive non-small cell lung cancer post-tumor resection.   This approval makes #Alecensa the first and only #ALKinhibitor authorized for this use. The decision follows impressive Phase III ALINA trial results, showing a remarkable 76% reduction in disease recurrence or death versus platinum-based chemotherapy. This milestone further solidifies #Genentech's position as a leader in #oncology innovation. #FDAApproval #LungCancer #Genentech #Alecensa #Oncology #Innovation #Lungcancer #NSCLC #RASLifescienceSolutions   Detailed News: https://lnkd.in/dvqmbpp2   Follow our page for more industry updates: https://lnkd.in/dGRWp6FD

The FDA approved #Alecensa (alectinib) for early-stage ALK-positive non-small cell lung cancer after tumor removal, making it the first ALK inhibitor for this use. Based on the Phase III ALINA trial, it showed a 76% reduction in disease recurrence or death compared to chemotherapy. This approval reinforces #Genentech's leadership in oncology innovation. ##FDAApproval #LungCancer #Genentech #Alecensa #Oncology #Innovation #Lungcancer #NSCLC #RASLifescienceSolutions   Detailed News: https://lnkd.in/dvqmbpp2   Follow our page for more industry updates: https://lnkd.in/dGRWp6FD

In case you missed it... 🎉 Big news in the world of oncology! The FDA has approved Genentech's Alecensa as the first ALK inhibitor for early-stage, ALK-positive non-small cell lung cancer post-surgery. 🚀 This follows impressive results from the Phase III ALINA trial where Alecensa reduced the risk of disease recurrence or death by a whopping 76% compared to traditional chemotherapy. It's not just about extending lives; it's about improving the quality of those years, with significant gains in central nervous system-disease-free survival. Genentech is on a roll, also showcasing strong data for Ocrevus and Columvi this week! #HealthcareInnovation #Oncology #FDAApproval #Genentech

The hottest cancer technology from the turn of the century is finally getting its glow-up moment: antibody-drug conjugates (ADCs) have been outperforming other available drugs across a range of indications, overturning decades of standards of care, and spurring pharma companies to spend $50 billion to snap up their share of the market. Read my latest article in AJMC - The American Journal of Managed Care to learn what this might mean for patients and the broader healthcare industry: https://bit.ly/4c4tUf3 #cancer #oncology #ADCs #pharma #biotech #cancerresearch

Exciting news from Eli Lilly and Company, announced (08/04/2023) Retevmo® (selpercatinib, a highly selective and potent RET kinase inhibitor) met its primary endpoint from a phase 3 #clinicaltrial (https://lnkd.in/gp7bByze) that demonstrated a statistically significant and clinically meaningful improvement progression-free survival (PFS) compared to a PD-1 inhibitor plus chemotherapy for adults with newly-diagnosed advanced or metastatic RET fusion-positive non-small cell lung cancer. 👍👍👍 Looking forward very much to seeing more results of secondary endpoints.

Paolo- this is so true! we now have technologies that can quantify the protein expression of all of the current repertoire of ADCs in the same tumor all at once: HER2, HER3, MET, TROP2, CLAUDIN18.2, TF, NECTIN4, FRalpha, MESOTHELIN, CEACAM, PSMA, LIV1, and many others. What are the ADC co-expression dynamics within the same tumor? how do these change after exposure to each ADC? does it even matter what the protein expression levels are? The sequencing will be incredibly interesting as will the resistance mechanisms that ultimately are likely to occur...

Datopotamab Deruxtecan Met Dual Primary Endpoint of Progression-Free Survival in Patients with Advanced Non Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial